
    
      This is a multi-center, randomized, double blind placebo-controlled and open label sevelamer
      hydrochloride-controlled, dose-ranging study in CKD patients with hyperphosphatemia on
      hemodialysis. Patients will be randomly allocated to one of the five treatment groups
      (ASP1585: 3 dose, placebo, Sevelamer hydrochloride) and advance to the 4-week treatment
      period.
    
  